Top Markets
Coin of the day
Enochian Biosciences, Inc. Enochian Biosciences, Inc.

Enochian Biosciences, Inc.

ENOB
주식 순위 #19951
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to... Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.
주가
$2.60
마지막 동기화: 2023-08-29
시가총액
$145.54M
변동 (1일)
9.24%
변동 (1년)
0.00%
국가
US
거래 Enochian Biosciences, Inc. (ENOB)

카테고리

Enochian Biosciences, Inc. (ENOB)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Enochian Biosciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Enochian Biosciences, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH